It adds something doctors already knew they were missing
In the long effort to make cancer treatment less of a blunt instrument and more of a precise one, a Houston-based diagnostics company has reached a meaningful threshold: independent, peer-reviewed validation that its EAIRR test reveals something about hormone-driven breast cancer that existing tools do not. Drawn from 659 patients in a major European clinical trial, the evidence suggests that knowing how sensitive a tumor is to endocrine therapy could meaningfully change which patients receive which treatments. The question now shifts from whether the science holds to whether the systems of medicine — hospitals, insurers, oncologists — will carry that knowledge into practice.
- Not all hormone receptor-positive breast cancer patients benefit equally from endocrine therapy, and the standard 21-gene Recurrence Score cannot reliably tell them apart — a gap with real consequences for treatment and survival.
- EAIRR's validation in a 659-patient trial, published in the European Journal of Cancer, demonstrated statistically significant added prognostic value beyond the existing standard, with a p-interaction below 0.001.
- The test proved meaningful even in harder-to-treat populations — premenopausal women and patients with four or more positive lymph nodes — expanding its potential reach in clinical settings.
- Achieving Level 1B evidence, the kind that oncologists and insurers weigh seriously, positions EAIRR as a credible candidate for routine adoption rather than a promising experiment.
- The immediate frontier is no longer scientific but institutional: whether cancer centers will order the test and whether payers will cover it as standard of care.
A Houston-based diagnostics company announced this week that its breast cancer biomarker test, EAIRR, has achieved independent clinical validation — a milestone that moves a promising tool closer to routine medical use. The validation, published in the European Journal of Cancer, analyzed samples from 659 patients enrolled in the PACS-01 clinical trial and found that EAIRR added meaningful prognostic information beyond what the widely used 21-gene Recurrence Score already provides.
The distinction matters because patients with hormone receptor-positive breast cancer are often prescribed endocrine therapy — drugs that block estrogen or progesterone from feeding tumor growth — but not all of them benefit equally. EAIRR measures how active hormones are within a tumor, identifying which patients are genuinely sensitive to endocrine therapy and which are not, a biological signal the Recurrence Score alone does not capture. The statistical significance was striking, with a p-interaction below 0.001.
The study's reach extended to populations that are typically more difficult to treat: premenopausal women and patients with four or more positive lymph nodes both showed prognostic value from the test. The evidence level achieved — Level 1B — carries weight with the oncologists and insurers who decide whether new diagnostics enter standard practice.
Delphi Diagnostics holds an exclusive license from MD Anderson Cancer Center to commercialize EAIRR, which was developed in the laboratory of Dr. W. Fraser Symmans. The company's chief medical officer described the publication as confirming that the test captures biological information about endocrine sensitivity that existing assays miss, with the potential to further personalize treatment decisions.
This marks the second independent prospective trial to demonstrate that EAIRR refines risk stratification beyond the Recurrence Score — the kind of external, peer-reviewed credibility that signals to clinicians and health systems that a test does what it claims. Whether that credibility translates into routine ordering and insurance coverage is the next, less scientific, but equally consequential question.
A Houston-based diagnostics company announced this week that its breast cancer test has cleared a significant scientific hurdle: independent validation in a major European journal. The test, called EAIRR, measures how active hormones are in a tumor and appears to tell doctors something important that existing tests miss.
The validation comes from analysis of 659 patient samples drawn from a large clinical trial called PACS-01. Researchers found that EAIRR provided meaningful prognostic information on top of what the standard 21-gene Recurrence Score already tells us. In other words, the new test didn't just repeat what doctors already knew—it added something. The study was published in the European Journal of Cancer under the title "Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the Recurrence Score in node-positive breast cancer: independent validation in the PACS-01 trial."
The stakes here are concrete. Breast cancer patients with hormone receptor-positive tumors often receive endocrine therapy—drugs that block estrogen or progesterone from fueling cancer growth. But not all patients benefit equally from these drugs. The EAIRR test appears to identify which patients are genuinely sensitive to endocrine therapy and which are not, a distinction the Recurrence Score alone does not make. In the study, the test strongly predicted which patients would benefit from adjuvant endocrine therapy, with statistical significance that researchers noted as p-interaction less than 0.001.
The validation also matters because it included patient groups that are often harder to treat: premenopausal women and patients with four or more positive lymph nodes. The test proved prognostic in both populations, broadening its potential clinical utility. The evidence level achieved—Level 1B—represents the kind of rigorous, prospective validation that oncologists and insurers take seriously when deciding whether to adopt a new test into practice.
Delphi Diagnostics, the company behind EAIRR, holds an exclusive license from MD Anderson Cancer Center in Houston to commercialize the technology, which was developed in the laboratory of Dr. W. Fraser Symmans. The company describes the test as measuring endocrine activity in stage II-III hormone receptor-positive, HER2-negative breast cancer. The measurement is then adjusted for baseline prognosis using molecular subtype genes and clinical factors like tumor size and lymph node involvement.
Federico Monzon, the company's chief medical officer, framed the publication as establishing that EAIRR captures biological information about endocrine sensitivity that existing assays do not. "This publication provides strong independent validation of EAIRR, establishing Level 1B evidence that it adds prognostic information, and underscores its ability to provide clinically actionable biological information that is not captured by existing assays," he said. He added that the test's ability to identify patients truly sensitive to endocrine therapy has the potential to further personalize treatment selection.
The validation is the second independent prospective clinical trial to show that EAIRR refines risk stratification in node-positive hormone receptor-positive breast cancer beyond the Recurrence Score. For a diagnostic test company, such independent validation—published in a peer-reviewed journal by researchers outside the company—is the currency of credibility. It signals to clinicians, hospital systems, and payers that the test does what it claims to do. The next phase will be whether hospitals and cancer centers begin ordering it routinely, and whether insurance companies agree to cover it as standard of care.
Notable Quotes
This publication provides strong independent validation of EAIRR, establishing Level 1B evidence that it adds prognostic information, and underscores its ability to provide clinically actionable biological information that is not captured by existing assays.— Federico A. Monzon, MD, Chief Medical Officer of Delphi Diagnostics
The Hearth Conversation Another angle on the story
So this test measures hormone activity in a tumor. Why does that matter more than what we already know from the Recurrence Score?
The Recurrence Score tells you the statistical likelihood that cancer will come back based on gene expression patterns. But it doesn't specifically measure how sensitive a tumor is to the drugs we use to treat it. EAIRR does that. It's the difference between knowing risk and knowing what will actually work.
And the study showed it works in harder-to-treat patients too—premenopausal women, patients with more lymph node involvement. Why is that important?
Because those are the patients where we're least certain about outcomes. If a test only works in easy cases, it's not that useful. Showing it works across different patient populations means it might actually change how we treat real people in the clinic.
The p-value was less than 0.001 for predicting endocrine therapy benefit. What does that mean in plain terms?
It means the relationship between the test result and who actually benefits from the drug is not a fluke. It's real, and it's strong. That's the kind of signal that makes doctors pay attention.
This is the second independent validation. Why does that word—independent—matter so much?
Because the first validation could have been a lucky result, or the company could have cherry-picked data. When a completely separate research team, using different patients, gets the same answer, it means the test is actually doing something, not just looking good on paper.
What happens now?
Hospitals and cancer centers have to decide whether to start using it. Insurance companies have to decide whether to pay for it. And that takes time. But this publication gives them the evidence they need to say yes.